Substituted pyrazolopyrimidines as akt kinase inhibitors

A compound of formula (I)

• in which
• R1 is hydrogen, a 1-6C-alkyl group,
• wherein said group being optionally substituted, one or more times, identically or differently, with a substituent selected from:
• hydroxy, halogen, 1-6C-alkyl, 1-4C-haloalkyl, 1-6C-alkoxy, —NR7R8, cyano, (═O), —C(O)NR7R8, —C(O)OR9, —NHC(O)R10, —NHS(O)2R10, heteroaryl,
• R2 is hydrogen, or a 1-6C-alkyl group
• wherein said group is optionally substituted, one or more times, identically or differently, with a substituent selected from:
• hydroxy, halogen, 1-6C-alkyl, 1-4C-haloalkyl, 1-6C-alkoxy, —NR7R8, cyano, —C(O)NR7R8, —C(O)OR9, —NHC(O)R10, —NHS(O)2R10, —NH-(1-6C-alkylen)-O-(1-6C-alkyl),
• R3 is hydrogen, 1-6C-alkyl which is optionally substituted one or more times with halogen,
• R4 is phenyl optionally substituted by 1-6C-alkyl, halogen, cyano,
• R5 is hydrogen, halogen,
• R6 is hydrogen, 1-6C-alkyl,
• X is —CH2—,
• Y is —CH2—, —CH(OH)—,
• R7, R8 which can be the same or different, is hydrogen, hydroxy, 3-7C-cycloalkyl or a group selected from 1-4C-alkyl, 1-6C-alkoxy, wherein said group is optionally substituted, one or more times, identically or differently, with a substituent selected from:
• halogen, hydroxy, mono- or di-(1-4C-alkylamino), 1-4C-alkoxy, or 3-7C-cycloalkyl or,
• R7 and R8 together with the nitrogen to which they are attached may also form a saturated or unsaturated 3-6C-heterocyclic ring,
• which is optionally substituted by (═O)
• R9 is hydrogen, 1-6C-alkyl,
• R10 is 1-4C-alkyl (optionally substituted in the same way of differently one or more times with halogen, hydroxy) or 3-7C-cycloalkyl,
• or an N-oxide, a salt, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer.